<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511975</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI188A103</org_study_id>
    <nct_id>NCT04511975</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS</brief_title>
  <official_title>A Phase 1b Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase 1b study to evaluate the safety, tolerability and preliminary&#xD;
      efficacy of IBI188 in combination with Azacitidine in newly diagnosed higher risk MDS&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    pause for further assessment and study adjustment&#xD;
  </why_stopped>
  <start_date type="Actual">August 24, 2020</start_date>
  <completion_date type="Anticipated">April 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events according to national Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 or customized AE severity grading as defined in the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of IBI188 in combination with AZA</measure>
    <time_frame>28 days</time_frame>
    <description>International Working Group (IWG) 2006 criteria will be used to evaluate efficacy of IBI188 in combination with AZA for response criteria for MDS</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>IBI188 + azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI188 in combination with azacitidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI188</intervention_name>
    <description>IBI188: 100 mg/mL, intravenous infusion once a week</description>
    <arm_group_label>IBI188 + azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle</description>
    <arm_group_label>IBI188 + azacitidine</arm_group_label>
    <other_name>VIDAZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed MDS subjects with higher risk.&#xD;
&#xD;
          2. Age ≥ 18 years old.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group score of 0-2.&#xD;
&#xD;
          4. Adequate organ function.&#xD;
&#xD;
          5. Subjects should take effective contraceptive measures.&#xD;
&#xD;
          6. Must sign the Informed Consent Form (ICF), and be able to follow all study procedures.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Subject who has transformed from MDS to AML.&#xD;
&#xD;
          2. MDS subjects with lower risk.&#xD;
&#xD;
          3. Subjects who have received chemotherapy.&#xD;
&#xD;
          4. History of chronic hemolytic anemia&#xD;
&#xD;
          5. Prior exposure to any anti-CD47 or anti-SIRPα agents.&#xD;
&#xD;
          6. Subjects participating in another interventional clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Luo</last_name>
    <role>Study Director</role>
    <affiliation>Innovent Biologics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland, PA</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Center for Cancer Research</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

